Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net Sales	$ 7,678.6	$ 7,394.2	$ 6,939.9
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of products sold, excluding intangible asset amortization	$ 2,191.2	$ 2,083.8	$ 2,019.5
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization	$ 591.9	$ 561.5	$ 526.8
Research and development	437.4	458.7	406.0
Selling, general and administrative	2,929.8	2,838.9	2,761.7
Goodwill and intangible asset impairment	0.0		292.8
Restructuring and other cost reduction initiatives	219.0	151.9	191.6
Quality remediation	0.0		33.8
Acquisition, integration, divestiture and related	23.6	21.7	11.4
Operating expenses	6,392.9	6,116.5	6,243.6
Operating Profit	1,285.7	1,277.7	696.3
Other expense, net	(31.1)	(9.3)	(128.0)
Interest expense, net	(218.0)	(201.2)	(164.8)
Earnings from continuing operations before income taxes	1,036.6	1,067.3	403.5
Provision for income taxes from continuing operations	131.4	42.2	112.3
Net Earnings from Continuing Operations	905.2	1,025.1	291.2
Less: Net earnings attributable to noncontrolling interest	1.5	1.1	1.0
Net Earnings from Continuing Operations of Zimmer Biomet Holdings, Inc.	903.8	1,024.0	290.2
Loss from Discontinued Operations, Net of Tax	0.0		(58.8)
Net Earnings of Zimmer Biomet Holdings, Inc.	$ 903.8	$ 1,024.0	$ 231.4
Basic Earnings Per Common Share
Earnings from Continuing Operations	$ 4.45	$ 4.91	$ 1.38
Loss from Discontinued Operations			(0.28)
Basic Earnings Per Common Share	4.45	4.91	1.1
Diluted Earnings Per Common Share
Earnings from Continuing Operations	4.43	4.88	1.38
Loss from Discontinued Operations			(0.28)
Diluted Earnings Per Common Share	$ 4.43	$ 4.88	$ 1.1
Weighted Average Common Shares Outstanding
Basic	203.1	208.7	209.6
Diluted	203.9	209.7	210.3